Cyclooxygenase 2 Inhibitors
"Cyclooxygenase 2 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.
| Descriptor ID |
D052246
|
| MeSH Number(s) |
D27.505.519.389.310.500 D27.505.696.663.850.014.040.500.500.500 D27.505.954.158.030.500.500 D27.505.954.329.030.500.500
|
| Concept/Terms |
Cyclooxygenase 2 Inhibitors- Cyclooxygenase 2 Inhibitors
- Inhibitors, Cyclooxygenase 2
- Cyclooxygenase-2 Inhibitors
- Inhibitors, Cyclooxygenase-2
- Coxibs
- COX-2 Inhibitors
- COX 2 Inhibitors
- Inhibitors, COX-2
- COX2 Inhibitors
- Inhibitors, COX2
|
Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase 2 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase 2 Inhibitors".
This graph shows the total number of publications written about "Cyclooxygenase 2 Inhibitors" by people in this website by year, and whether "Cyclooxygenase 2 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclooxygenase 2 Inhibitors" by people in Profiles.
-
Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials. Int J Mol Sci. 2020 Dec 17; 21(24).
-
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives. Int J Mol Sci. 2018 Aug 08; 19(8).
-
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):291-297.
-
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget. 2015 Oct 20; 6(32):33290-305.
-
"First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. Am J Epidemiol. 2014 Sep 15; 180(6):636-44.
-
Cardiovascular disease and non-steroidal anti-inflammatory drug prescribing in the midst of evolving guidelines. J Eval Clin Pract. 2013 Dec; 19(6):1026-34.
-
Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia. 2012 Sep; 14(9):778-87.
-
Low-volume binary drug therapy for the treatment of hypovolemia. Shock. 2011 Jun; 35(6):590-6.
-
Briarane diterpenes diminish COX-2 expression in human colon adenocarcinoma cells. J Nat Prod. 2011 Apr 25; 74(4):857-61.
-
Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition. Brain. 2010 Aug; 133(Pt 8):2264-80.